The myelofibrosis drug landscape has become more crowded since Syntara decided to focus on the disease in 2020, but the ...

While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...

Explore the promising potential of Altimmune, Inc.'s Pemvidutide in NASH, AUD, & obesity treatment, with key trials underway.

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

The U.S. dollar remains near a five-month low due to President Trump's unpredictable trade policies and weak economic data. The euro is close to a five-month high following Germany's fiscal agreement ...